Bone Biologics Corp

We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (“DBM”) is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the U.S. Food and Drug Administration (“FDA”) that NELL-1/DBM will be classified as a device/drug combination product that will require an FDA-approved pre-market approval (“PMA”) application before it can be commercialized in the United States.

Current securities

1. 10-Q filingOct 26, 2026
2. 25-NSE - filed by Nasdaq Stock Market LLC regarding Bone Biologics CorpOct 13, 2026
3. Submission of Matters to a Vote of Security HoldersSep 29, 2026
4. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 16, 2026
5. PRE 14A filingAug 18, 2026